News
AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...
Taiho-developed TAS-205 is designed to selectively inhibit hematopoietic prostaglandin D synthase (HPGDS), an enzyme related ...
At the halfway mark last year, 97 layoff rounds were reported, marking a 32% year-over-year increase for the first half of ...
The FDA has cleared its first cuffless blood pressure monitor that will be available over-the-counter, with the Hilo ...
At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the ...
Cargo will mark the latest in a string of acquisitions for the deal-hungry Concentra. So far this year, Concentra has signed ...
Alcon has inked a deal to acquire LumiThera and its light-based therapy for dry age-related macular degeneration, which obtained a groundbreaking FDA clearance late last year. | LumiThera's approach ...
Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.
Following long-time chief José Almeida’s retirement earlier this year, Baxter announced it has officially named a new CEO. | ...
Headlands Research, a clinical trial site network with locations across the U.S. and Canada, has made its first step into the ...
Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell ...
Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results